Integra Lifesciences IART Earnings Analysis

Earnings Analysis for IART – Last 3 Years

1. Revenue Analysis:

Total and Operating Revenue: IART’s Operating and Total Revenue has shown slight variability across the periods, peaking in Q3 2023 with $382.42M and reaching its lowest at $368.87M in Q1 2024. The revenue trend indicates fluctuations but not a consistent direction in growth or decline.

Gross Profit Margins: The Gross Profit Margin saw its highest in Q1 2023 with $232.87M but dipped to $206.83M by Q1 2024, reflecting possible challenges in maintaining profit margins or varying costs.

2. Cost Management:

Cost of Revenue: The Cost of Revenue peaked at $174.24M in Q2 2023 but was notably reduced in subsequent quarters, at $162.04M by Q1 2024, showing effective cost management strategies.

Operating Expense: Operating expenses recorded a high of $202.87M in Q1 2024 from a lower $191.75M in Q3 2023. This rise could indicate increased operational activities or cost pressures.

Total Expenses: Generally increasing, Total Expenses amounted to $364.91M in Q1 2024 from $344.46M in Q1 2023, signaling growing operational costs over the years.

3. Profitability Analysis:

EBITDA: EBITDA notably decreased from $73.59M in Q1 2023 to $38.96M by Q1 2024. This substantial fall suggests operational or market challenges impacting profitability.

Operating Income: Follows the trend in EBITDA, with a peak at $36.38M in Q1 2023 but falling to $3.96M by Q1 2024.

Pretax Income and Net Income: Reflecting the overall declining profitability trend, Pretax Income and Net Income also significantly dropped. Interestingly, there was a shift to negative Net Income of -$3.28M in Q1 2024 from a healthy $24.23M in Q1 2023.

4. Cash Flow Indicators:

Reconciled Depreciation: Remained relatively stable over the periods, a slight variance indicating stable capital expense depreciation methods.

Interest Expense: This has consistently remained a significant cost, increasing the financial strain. There was a slight decrease seen in Q1 2024.

5. Taxation:

Tax Rate: The Effective Tax Rate varied, lower rates in 2023 (around 21%) compared to 37.3% in Q1 2024, potentially affecting the net income available after tax.

Tax Provision: Varied in response to pretax income, with notable income tax provisions aligning with profitability decreases.

6. Shareholder Metrics:

Diluted and Basic EPS: There was a significant drop in EPS, turning negative at -0.04 in Q1 2024 from a positive 0.29 in Q1 2023, reflecting the tougher financial conditions and lowered profitability.

Average Shares: The Average Shares outstanding had slight fluctuations, suggesting no major stock buybacks or issues over the period.

Net Income Available to Common Stockholders: Echoing the Net Income trends, available income for stockholders turned negative in Q1 2024, highlighting profitability concerns.

7. Conclusion:

The financial analysis of IART over the past three years reveals strain in managing costs and maintaining profitability amidst varying revenue performance. Strategic review of operational efficiencies, cost management, and perhaps a reconsideration of investment activities may be necessary to bolster the financial foundations and reassure shareholder interests.

Appendices:

Due to format constraints, detailed tables and calculations are not displayed. However, these would typically include line items breakdown from the provided data for a comprehensive view and verification.